100 related articles for article (PubMed ID: 8438092)
21. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Hirst VK; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1105-8. PubMed ID: 3017904
[TBL] [Abstract][Full Text] [Related]
22. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
[TBL] [Abstract][Full Text] [Related]
23. DNA damage induced in T50/80 tumour cells following exposure to the bioreductive drug Tirapazamine in combination with a single dose of radiation (12Gy).
Friery OP; Hejmadi MV; McKeown SR
Biochem Soc Trans; 1997 Feb; 25(1):135S. PubMed ID: 9057033
[No Abstract] [Full Text] [Related]
24. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
Riley RJ; Hemingway SA; Graham MA; Workman P
Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
[TBL] [Abstract][Full Text] [Related]
25. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
26. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
27. Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR 4233) and radiation.
Senan S
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):209-10. PubMed ID: 7995763
[No Abstract] [Full Text] [Related]
28. Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air.
Tuttle SW; Hazard L; Koch CJ; Mitchell JB; Coleman CN; Biaglow JE
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):357-62. PubMed ID: 8195033
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton MI; Workman P
J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
31. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
Zeman EM; Lemmon MJ; Brown JM
Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
[TBL] [Abstract][Full Text] [Related]
32. Hypobaric hypoxia: a method for testing bioreductive drugs in vivo.
McAleer JJ; McKeown SR; MacManus MP; Lappin TR; Bridges JM
Int J Radiat Oncol Biol Phys; 1992; 23(3):551-5. PubMed ID: 1612955
[TBL] [Abstract][Full Text] [Related]
33. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
[TBL] [Abstract][Full Text] [Related]
34. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.
Khan S; O'Brien PJ
Br J Cancer; 1995 Apr; 71(4):780-5. PubMed ID: 7710944
[TBL] [Abstract][Full Text] [Related]
37. Improving the effectiveness of the bioreductive antitumor agent SR 4233 by induced hypoxia.
Minchinton AI; Brown JM
Adv Exp Med Biol; 1992; 317():177-81. PubMed ID: 1288125
[No Abstract] [Full Text] [Related]
38. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.
Walton MI; Wolf CR; Workman P
Biochem Pharmacol; 1992 Jul; 44(2):251-9. PubMed ID: 1642640
[TBL] [Abstract][Full Text] [Related]
39. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study.
Lee DJ; Trotti A; Spencer S; Rostock R; Fisher C; von Roemeling R; Harvey E; Groves E
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):811-5. PubMed ID: 9845102
[TBL] [Abstract][Full Text] [Related]
40. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
